Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAVERS: AM-125 for acute peripheral vertigo following neurosurgery
2018-002474-52Phase 2Completed
- Sponsor
- Altamira Therapeutics
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of betahistine intranasal in vestibular vertigo and Acute peripheral vertigo (2 arms), sponsored by Altamira Therapeutics. Primary endpoint: Primary efficacy endpoint. Started Jan 2019; status: completed.
02
Drugs
betahistine intranasal
03
Conditions
vestibular vertigoAcute peripheral vertigo
Beyond the preview
Go deeper on 2018-002474-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002474-52.